Company intelligence / Profile preview

Rigerna Therapeutics

Beijing, Beijing Shi, Chinarigerna.com ↗

Ownership: Private
Development stage: Other

Overview

Rigerna has launched Phase 1 trial dosing for RG002 (C3-siRNA) for IgA nephropathy. The company has also completed Proof-of-Concept experiments for its proprietary kidney-targeting siRNA platform in Non-human Primates.

Therapeutic areas: Metabolic DisordersNephrology
Modalities: siRNARNA interference (RNAi)
Industry: Biotech

Drug pipeline

8 assets

RG002C0106

7 more assets in the full pipeline.

Request access →

Partnerships

Beijing Institute of Technology

Beyond the preview

Go deeper on Rigerna Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rigerna Therapeutics.

Explore the full profile